Skip to main content
. Author manuscript; available in PMC: 2020 Aug 14.
Published in final edited form as: Leukemia. 2020 Feb 14;34(7):1741–1750. doi: 10.1038/s41375-020-0741-0

Table 4.

Multivariable analysis for overall survival from EOI and EOC

Characteristic1 n (%) Overall Survival from EOI Overall Survival from EOC
HR 95% CI p-value HR 95% CI p-value
Age at diagnosis <10 years 39 (49) 1 -- 0.917 1 -- 0.893
≥10 years 41 (51) 1.1 0.19, 6.25 1.13 0.19, 6.55
Initial WBC (/uL) <50,000 57 (71) 1 -- 0.372 1 -- 0.396
≥50,000 23 (29) 0.44 0.07, 2.69 0.45 0.07, 2.91
Cytogenetic classification2 Neutral 59 (74) 1 -- 0.163 1 -- 0.165
Favorable 15 (19) 0.54 0.05, 5.37 0.53 0.05, 5.38
Adverse 6 (7) 7.61 1.02, 56.64 7.68 1.01, 58.16
Induction therapy3 COG SR 26 (32) 1 -- 0.561 1 -- 0.567
COG HR 54 (68) 2.05 0.18, 22.75 2.05 0.18, 23.47
HSCT in CR14 No 69 (89) 1 -- 0.674 1 -- 0.712
Yes 11 (14) 1.44 0.26, 7.87 1.4 0.24, 8.15
EOI MRD5 Negative 57 (71) 1 -- 0.003 -- -- --
Positive 23 (29) 9.57 1.94, 47.20 -- --
EOI/EOC MRD5 neg/neg 57 (71) -- -- -- 1 -- 0.028
pos/neg 13 (16) -- -- -- 9.32 1.45, 59.85
pos/pos 3 (4) -- -- -- 10.03 0.64, 157.42
pos/unk. 7 (9) -- -- -- 9.94 1.51, 65.47
1

All candidate predictors in Table 1 tested in stepwise multivariable model with endpoint of OS, see methods. Age, WBC, cytogenetics included as a priori “base” model irrespective of significance.

2

As per AALL08B1 criteria; excludes two patients with unknown cytogenetics.

3

COG SR/HR = Children’s Oncology Group three drug (steroid, vincristine, asparaginase) or four drug induction (+daunorubicin) for NCI/Rome Standard Risk or High Risk ALL

4

Hematopoetic stem cell transplantation (HSCT) in first remission (CR1).

5

MRD considered positive ≥0.01% at either time-point. EOI = end of induction, EOC = end of consolidation WBC = white blood cell count.